Abstract
In The Lancet, the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) report meta-analyses of outcomes in 100 000 women with early breast cancer in more than 100 trials of adjuvant chemotherapy,1 which include the first EBCTCG meta-analyses of adjuvant taxane treatment. This study comes 35 years after the first report of the benefit of adjuvant chemotherapy,2 and is the 16th publication in the group's 28-year history of bringing together individual patient data from all randomised trials worldwide.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
